StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) shareholders

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
83.2%
41M of 49M shares
Institutional holders
72
39 new, 7 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
22 buys · 22 sales
Net bought $106.34M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (37.90%), Rajeev Shah (37.90%) and 1 more
18,415,95637.90%13D (active) amendmentJul 22, 2026
Rajeev Shah
Joint filing with RA Capital Management, L.P. (36.60%), Peter Kolchinsky (36.60%) and 1 more
17,811,62336.60%13D (active) amendmentJun 11, 2026
GC Corp
Joint filing with Yong-Jun Huh (12.30%)
5,999,70312.30%13D (active) amendmentMay 11, 2026
Viking Global Opportunities Parent GP LLC
Joint filing with Viking Global Investors LP (5.40%), Halvorsen Ole Andreas (5.40%) and 1 more
2,604,1665.40%13G (passive)May 11, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ARTVValueChange% of portfolio
Ra Capital Management, L.P.17,955,64236.73%$174.17M+8,102,3401.51%
Viking Global Investors LP2,604,1665.33%$25.26MNew0.07%
Blackstone Inc.2,403,4374.92%$23.31MNew0.07%
5AM Venture Management, LLC2,353,3044.81%$22.83M–7.93%
VR Adviser, LLC2,043,5964.18%$19.82M+434,0270.60%
Franklin Resources Inc1,997,2234.09%$19.37M+1,476,8960.00%
Caligan Partners LP1,736,1113.55%$16.84MNew0.79%
Vanguard Capital Management LLC981,8152.01%$9.52M+774,1290.00%
Samsara BioCapital, LLC954,8611.95%$9.26MNew0.76%
Blue Owl Capital Holdings LP874,5421.79%$8.48MNew1.28%
Propel Bio Management, LLC696,4361.42%$6.76M+550,0673.54%
BlackRock, Inc.694,7261.42%$6.74M+481,3380.00%
Citadel Advisors LLC609,3761.25%$5.91M+593,5060.00%
Nantahala Capital Management, LLC600,0001.23%$5.82MNew0.10%
Silverarc Capital Management, LLC525,0001.07%$5.09MNew0.53%
Geode Capital Management, LLC353,8450.72%$3.43M+252,1500.00%
Boothbay Fund Management, LLC314,3750.64%$3.05MNew0.04%
Revelation Capital Management, LLC299,3110.61%$2.90M–2.65%
Alyeska Investment Group, L.P.273,6150.56%$2.65M+173,6150.01%
Acuta Capital Partners, LLC260,4160.53%$2.53MNew1.76%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267241M83.2%39 / 252 / 725M1M
Q1 20264017M34.4%12 / 312 / 51M0M
Q4 20253417M34.7%6 / 415 / 121M2M
Q3 20254018M37.1%6 / 816 / 141M1M
Q2 20254819M37.9%12 / 916 / 171M3M
Q1 20255321M42.8%4 / 2212 / 71M1M
Q4 20245721M43.3%9 / 186 / 10M0M
Q3 20244921M42.4%49 / 00 / 021M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

50 funds held ARTV in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ARTVValue% of fundAs of
Vanguard Total Stock Market Index Fund699,8991.43%$6.79M0.00%Jun 30, 2026
Franklin Biotechnology Discovery Fund542,3711.11%$5.48M0.47%Jul 31, 2026
Franklin Small Cap Growth Fund456,4680.93%$4.61M0.19%Jul 31, 2026
Vanguard Extended Market Index Fund269,1490.55%$2.61M0.00%Jun 30, 2026
iShares Russell 2000 ETF140,5930.29%$1.36M0.00%Jun 30, 2026
Simplify Propel Opportunities ETF101,3550.21%$983.14K1.27%Jun 30, 2026
Fidelity Small Cap Index Fund51,5570.11%$520.73K0.00%Jul 31, 2026
Ultra-Small Company Fund50,0000.10%$485.00K0.49%Jun 30, 2026
Ultra-Small Company Market Fund35,0000.07%$339.50K0.23%Jun 30, 2026
Fidelity Extended Market Index Fund30,8950.06%$245.00K0.00%May 31, 2026
U.S. Micro Cap Portfolio27,4260.06%$277.00K0.00%Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund23,0150.05%$223.25K0.01%Jun 30, 2026
iShares Russell 2000 Value ETF20,8250.04%$202.00K0.00%Jun 30, 2026
Nationwide Bailard Small Cap Value Fund20,7000.04%$209.07K0.16%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund16,2580.03%$128.93K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Fred AslanChief Executive Officer, Director1,457,4282.98%Nov 3, 2026
Subhashis BanerjeeChief Medical Officer168,7380.35%Nov 3, 2026
Jennifer BushCOO, CLO, Compliance Officer357,7200.73%Nov 3, 2026
Christopher HoranChief Tech Operations Officer302,3210.62%Nov 3, 2026
Gines Diego MirallesPresident & Head of R&D122,5000.25%Sep 11, 2026
Heather RaymonSVP, Research and Development148,2280.30%May 19, 2026
Thad Allen HustonChief Financial Officer220,0000.45%Mar 10, 2026
Neha KrishnamohanChief Financial Officer99,3560.20%Nov 17, 2025
Thorsten GraefChief Medical Officer80,0000.16%Feb 28, 2025
Capital Healthcare Fund LP RADirector, 10% owner17,329,57035.45%Sep 14, 2026
Alison MooreDirector––Sep 14, 2026
Elaine K. SorgDirector––Sep 14, 2026
Brian DanielsDirector––Sep 14, 2026
Rajeev M. ShahDirector, 10% owner16,817,57334.40%Sep 14, 2026
RA Capital Nexus Fund III, L.P.Director17,283,80235.35%Sep 14, 2026
Peter KolchinskyDirector, 10% owner17,242,48335.27%Sep 14, 2026
RA Capital Nexus Fund, L.P.Director16,817,54334.40%Sep 14, 2026
Ra Capital Management, L.P.Director, 10% owner16,795,91934.35%Sep 14, 2026
Daniel G. BakerDirector––Sep 14, 2026
Laura StoppelDirector––Sep 14, 2026
Elizabeth L. HougenDirector––Sep 14, 2026
Corp. GC10% owner5,999,70312.27%May 28, 2026
Cell Corp GC10% owner1,541,3713.15%May 28, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Christopher Horan
Chief Tech Operations Officer
Nov 2, 2026Sale−10,423$4.18$43.58K302,321
Jennifer Bush
COO, CLO, Compliance Officer
Nov 2, 2026Sale−8,439$4.18$35.28K357,720
Subhashis Banerjee
Chief Medical Officer
Nov 2, 2026Sale−1,110$4.18$4.64K168,738
Fred Aslan
Chief Executive Officer, Director
Nov 2, 2026Sale−62,178$4.18$259.97K1,457,428
Fred Aslan
Chief Executive Officer, Director
Oct 6, 2026Sale(10b5-1 plan)−23,463$7.20$168.88K1,519,606
Christopher Horan
Chief Tech Operations Officer
Oct 5, 2026Sale−10,340$6.84$70.70K312,744
Jennifer Bush
COO, CLO, Compliance Officer
Oct 5, 2026Sale−8,370$6.84$57.23K366,159
Subhashis Banerjee
Chief Medical Officer
Oct 5, 2026Sale−1,099$6.84$7.51K169,848
Fred Aslan
Chief Executive Officer, Director
Oct 5, 2026Sale−61,696$6.84$421.83K1,543,069
Fred Aslan
Chief Executive Officer, Director
Sep 15, 2026Award+110,000––1,604,765
Fred Aslan
Chief Executive Officer, Director
Sep 10, 2026Award+45,000––1,494,765
Gines Diego Miralles
President & Head of R&D
Sep 9, 2026Award+45,000––122,500
Subhashis Banerjee
Chief Medical Officer
Sep 9, 2026Award+30,000––170,947
Christopher Horan
Chief Tech Operations Officer
Sep 9, 2026Award+40,000––323,084
Jennifer Bush
COO, CLO, Compliance Officer
Sep 9, 2026Award+45,000––374,529
Fred Aslan
Chief Executive Officer, Director
Sep 8, 2026Sale(10b5-1 plan)−23,429$10.92$255.84K1,449,765
Jennifer Bush
COO, CLO, Compliance Officer
Sep 3, 2026Sale−8,391$11.16$93.64K329,529
Subhashis Banerjee
Chief Medical Officer
Sep 3, 2026Sale−1,100$11.16$12.28K140,947
Christopher Horan
Chief Tech Operations Officer
Sep 3, 2026Sale−10,366$11.16$115.68K283,084
Fred Aslan
Chief Executive Officer, Director
Sep 3, 2026Sale−61,888$11.16$690.67K1,473,194
Subhashis Banerjee
Chief Medical Officer
Aug 27, 2026Sale(10b5-1 plan)−8,222$12.01$98.75K142,047
Subhashis Banerjee
Chief Medical Officer
Aug 27, 2026Option exercise+5,306$1.92$10.19K150,269
Subhashis Banerjee
Chief Medical Officer
Aug 18, 2026Option exercise+429$1.92$824145,392
Subhashis Banerjee
Chief Medical Officer
Aug 18, 2026Sale(10b5-1 plan)−429$12.00$5.15K144,963
Capital Healthcare Fund LP RA
Director, 10% owner
Jul 31, 2026Buy+24,944$9.93$247.69K17,329,570
Capital Healthcare Fund LP RA
Director, 10% owner
Jul 29, 2026Buy+20,824$9.99$208.03K17,304,626
RA Capital Nexus Fund III, L.P.
Director
Jul 24, 2026Buy+41,319$9.99$412.78K17,283,802
Peter Kolchinsky
Director, 10% owner
Jul 23, 2026Buy+59,880$9.96$596.40K17,242,483
Peter Kolchinsky
Director, 10% owner
Jul 22, 2026Buy+84,124$9.93$835.35K17,182,603
Peter Kolchinsky
Director, 10% owner
Jul 21, 2026Buy+120,582$9.55$1.15M17,098,479
Capital Healthcare Fund LP RA
Director, 10% owner
Jul 17, 2026Buy+7,882$8.95$70.54K16,977,927
Capital Healthcare Fund LP RA
Director, 10% owner
Jul 16, 2026Buy+152,472$8.93$1.36M16,970,045
RA Capital Nexus Fund, L.P.
Director
Jul 13, 2026Buy+6,522$8.94$58.31K16,817,543
Rajeev M. Shah
Director, 10% owner
Jul 13, 2026Buy+6,552$8.94$58.57K16,817,573
Rajeev M. Shah
Director, 10% owner
Jul 10, 2026Buy+15,102$8.97$135.46K16,811,021
Ra Capital Management, L.P.
Director, 10% owner
Jun 26, 2026Buy+1,876$8.98$16.85K16,795,919
Ra Capital Management, L.P.
Director, 10% owner
Jun 25, 2026Buy+31,000$8.88$275.28K16,794,043
Peter Kolchinsky
Director, 10% owner
Jun 16, 2026Buy+124,893$8.89$1.11M16,763,043
Peter Kolchinsky
Director, 10% owner
Jun 15, 2026Buy+15,414$8.99$138.57K16,638,150
Peter Kolchinsky
Director, 10% owner
Jun 12, 2026Buy+391,019$8.57$3.35M16,622,736
RA Capital Nexus Fund, L.P.
Director
Jun 11, 2026Buy+548,580$7.91$4.34M16,231,717
RA Capital Nexus Fund, L.P.
Director
Jun 10, 2026Buy+103$7.00$72115,683,137
RA Capital Nexus Fund, L.P.
Director
Jun 9, 2026Buy+479,039$6.91$3.31M15,683,034
Fred Aslan
Chief Executive Officer, Director
May 19, 2026Sale−27,116$9.01$244.32K1,535,082
Christopher Horan
Chief Tech Operations Officer
May 19, 2026Sale−7,002$9.01$63.09K293,450
Jennifer Bush
COO, CLO, Compliance Officer
May 19, 2026Sale−8,790$9.01$79.20K337,920
Heather Raymon
SVP, Research and Development
May 19, 2026Sale−3,095$9.01$27.89K148,228
Subhashis Banerjee
Chief Medical Officer
May 19, 2026Sale−7,037$9.01$63.40K144,963
Gines Diego Miralles
President & Head of R&D
May 18, 2026Award+77,500––77,500
Corp. GC
10% owner
May 11, 2026Buy+347,222$11.52$4.00M1,607,734
Corp. GC
10% owner
May 11, 2026Buy+1,085,069$11.52$12.50M4,391,969
RA Capital Nexus Fund III, L.P.
Director
May 11, 2026Buy+6,510,416$11.52$75.00M15,203,995
Thad Allen Huston
Chief Financial Officer
Mar 10, 2026Award+220,000––220,000
Subhashis Banerjee
Chief Medical Officer
Feb 15, 2026Award+102,000––152,000
Jennifer Bush
COO, CLO, Secy, Compliance Off
Feb 15, 2026Tax withholding−3,515$4.00$14.06K346,710
Jennifer Bush
COO, CLO, Secy, Compliance Off
Feb 15, 2026Award+117,300––350,225
Christopher Horan
Chief Tech Operations Officer
Feb 15, 2026Award+117,300––302,639
Christopher Horan
Chief Tech Operations Officer
Feb 15, 2026Tax withholding−2,187$4.00$8.75K300,452
Fred Aslan
President and CEO, Director
Feb 15, 2026Award+366,850––1,576,798
Fred Aslan
President and CEO, Director
Feb 15, 2026Tax withholding−14,600$4.00$58.40K1,562,198

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
19.04%
3M shares short
Days to cover
1.8
At 2M shares a day
Change since last report
+7.9%
From 3M shares
Short volume, 20 days
40.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Artiva Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 19,516 shares on Sep 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Fred Aslan
Director, Officer
Oct 6, 202634,465$245.74KOct 6, 2026Restricted Stock Units
Fred Aslan
Director, Officer
Sep 8, 202623,429$262.17KSep 8, 2026Restricted Stock Units
Subhashis Banerjee
Officer
Aug 27, 20267,818$92.02KAug 27, 2026Exercise of Stock Options
Subhashis Banerjee
Officer
Aug 18, 2026833$9.78KAug 18, 2026Exercise of Stock Options
Fred Aslan
Officer, Director
May 18, 202628,000$258.16KMay 18, 2026Restricted Stock Units vesting under registered plan
Subhashis Banerjee
Officer, Director
May 18, 20267,000$64.54KMay 18, 2026Restricted Stock Units vesting under registered plan
Jennifer Bush
Officer, Director
May 18, 20269,000$82.98KMay 18, 2026Restricted Stock Units vesting under registered plan
Christopher Horan
Officer, Director
May 18, 20267,500$69.15KMay 18, 2026Restricted Stock Units vesting under registered plan
Heather Raymon
Officer, Director
May 18, 20263,500$32.27KMay 18, 2026Restricted Stock Units vesting under registered plan
Fred Aslan
Director, Officer
Dec 15, 202512,749$42.07KDec 15, 2025Restricted Stock Units
Fred Aslan
Director, Officer
Nov 17, 20256,375$20.72KNov 17, 2025Restricted Stock Units
Fred Aslan
Director, Officer
Oct 17, 202525,500$70.64KOct 17, 2025Restricted Stock Units
Fred Aslan
Director, Officer
Aug 15, 202525,500$68.85KAug 15, 2025Restricted Stock Units

See a number that looks wrong?